Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 2
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state.
Yu W, Chen Y, Putluri N, Osman A, Coarfa C, Putluri V, Kamal AHM, Asmussen JK, Katsonis P, Myers JN, Lai SY, Lu W, Stephan CC, Powell RT, Johnson FM, Skinner HD, Kazi J, Ahmed KM, Hu L, Threet A, Meyer MD, Bankson JA, Wang T, Davis J, Parker KR, Harris MA, Baek ML, Echeverria GV, Qi X, Wang J, Frederick AI, Walsh AJ, Lichtarge O, Frederick MJ, Sandulache VC. Yu W, et al. Br J Cancer. 2023 Jun;128(11):2013-2024. doi: 10.1038/s41416-023-02253-7. Epub 2023 Apr 3. Br J Cancer. 2023. PMID: 37012319 Free PMC article.
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer.
Echeverria GV, Cai S, Tu Y, Shao J, Powell E, Redwood AB, Jiang Y, McCoy A, Rinkenbaugh AL, Lau R, Trevarton AJ, Fu C, Gould R, Ravenberg EE, Huo L, Candelaria R, Santiago L, Adrada BE, Lane DL, Rauch GM, Yang WT, White JB, Chang JT, Moulder SL, Symmans WF, Hilsenbeck SG, Piwnica-Worms H. Echeverria GV, et al. NPJ Breast Cancer. 2023 Jan 10;9(1):2. doi: 10.1038/s41523-022-00502-1. NPJ Breast Cancer. 2023. PMID: 36627285 Free PMC article.
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.
Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, Vashist TD, Huynh AMT, Dou Y, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs RA, Muzny DM, Doddapaneni H, Dobrolecki LE, Rodriguez H, Robles AI, Hiltke T, Lewis MT, Nangia JR, Nemati Shafaee M, Li S, Hagemann IS, Hoog J, Lim B, Osborne CK, Mani DR, Gillette MA, Zhang B, Echeverria GV, Miles G, Rimawi MF, Carr SA, Ademuyiwa FO, Satpathy S, Ellis MJ. Anurag M, et al. Cancer Discov. 2022 Nov 2;12(11):2586-2605. doi: 10.1158/2159-8290.CD-22-0200. Cancer Discov. 2022. PMID: 36001024 Free PMC article.
Subclonal heterogeneity and evolution in breast cancer.
Mavrommati I, Johnson F, Echeverria GV, Natrajan R. Mavrommati I, et al. NPJ Breast Cancer. 2021 Dec 21;7(1):155. doi: 10.1038/s41523-021-00363-0. NPJ Breast Cancer. 2021. PMID: 34934048 Free PMC article. Review.
Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer.
Powell RT, Redwood A, Liu X, Guo L, Cai S, Zhou X, Tu Y, Zhang X, Qi Y, Jiang Y, Echeverria G, Feng N, Ma X, Giuliani V, Marszalek JR, Heffernan TP, Vellano CP, White JB, Stephan C, Davies PJ, Moulder S, Symmans WF, Chang JT, Piwnica-Worms H. Powell RT, et al. Sci Rep. 2020 Oct 21;10(1):17899. doi: 10.1038/s41598-020-74882-4. Sci Rep. 2020. PMID: 33087803 Free PMC article.